A Phase 1 Study of IPI-926 in Patients With Advanced and/or Metastatic Solid Tumor Malignancies
| Status: | Archived |
|---|---|
| Conditions: | Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
| Start Date: | September 2008 |
| End Date: | June 2011 |
The primary objectives of the study are:
- To determine the safety and the maximum tolerated dose (MTD) of IPI-926
- To examine the pharmacokinetic parameters of IPI-926 and its characterized major
metabolite(s)
- To recommend a dose and schedule of IPI-926 for subsequent studies
Study IPI-926-01 is a Phase 1, open-label, dose-escalation study in patients with advanced
and/or metastatic solid tumor malignancies.
We found this trial at
4
sites
University of Colorado, Boulder As the flagship university of the state of Colorado, CU-Boulder is...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials